Clinical Trial

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Study acronym: AXemplify-357
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
Protocol Amendment History 2 changes
notable Trial sites expanded: 119 -> 122 locations 2026-05-27
notable Trial sites expanded: 115 -> 118 locations 2026-04-07
Trial Details
NCT Number NCT06585774
Lead Sponsor Incyte Corporation
Conditions Chronic Graft-versus-host-disease
Enrollment 240 participants
Start Date 2025-01-21
Primary Completion 2027-09-28 (estimated)
Study Completion 2030-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-06